Cancers & treatments·Regimen libraryFirst line

Enfortumab vedotin + pembrolizumab

Checked 2026-09-09

Locally advanced or metastatic urothelial cancer, first line, regardless of cisplatin eligibility

One cycle

every 21 days

21-day cycle, until progression; pembrolizumab up to 35 cyclesIntravenous

Components

Drug	Dose	Route	Days	Note
Enfortumab vedotin ADC	1.25 mg/kg (maximum 125 mg)	IV	D1, 8
Pembrolizumab Monoclonal antibody (anti-PD-1)	200 mg	IV	D1	or 400 mg every 6 weeks

Cycles

until progression; pembrolizumab up to 35 cycles

21-day cycle

Emetogenicity

Low (10-30%)

G-CSF

Not routine

Notes

Skin reactions (including SJS/TEN), peripheral neuropathy and hyperglycaemia are enfortumab's signals; hold for glucose above 13.9 mmol/L (250 mg/dL).

Used in

Bladder & urothelial cancer

Trials

EV-302 / KEYNOTE-A39

Products

Enfortumab vedotinPembrolizumab

Source

EV-302 / KEYNOTE-A39, NEJM 2024

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

Gemcitabine + cisplatin

Advanced biliary tract cancer first line (with durvalumab or pembrolizumab); cisplatin-eligible urothelial cancer

every 21 days × 8

Sacituzumab govitecan

Metastatic TNBC after two lines (one for metastatic disease); HR-positive after endocrine therapy and two chemotherapies

every 21 days

Dose-dense MVAC

Muscle-invasive bladder cancer, cisplatin-eligible, before cystectomy

every 14 days × 3-4

Intravesical BCG, induction and maintenance

High-risk non-muscle-invasive bladder cancer after complete TURBT

weekly × 6

All regimens Intravesical BCG, induction and maintenance →